Epirus Biopharmaceuticals (NASDAQ: EPRS) and Anavex Life Sciences Corp. (NASDAQ:AVXL) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.

Valuation & Earnings

This table compares Epirus Biopharmaceuticals and Anavex Life Sciences Corp.’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Epirus Biopharmaceuticals N/A N/A N/A ($2.53) -0.06
Anavex Life Sciences Corp. N/A N/A -$15.61 million ($0.39) -11.79

Anavex Life Sciences Corp. is trading at a lower price-to-earnings ratio than Epirus Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Epirus Biopharmaceuticals and Anavex Life Sciences Corp., as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Epirus Biopharmaceuticals 0 0 0 0 N/A
Anavex Life Sciences Corp. 0 0 3 0 3.00

Anavex Life Sciences Corp. has a consensus target price of $13.67, indicating a potential upside of 197.10%. Given Anavex Life Sciences Corp.’s higher probable upside, analysts clearly believe Anavex Life Sciences Corp. is more favorable than Epirus Biopharmaceuticals.

Profitability

This table compares Epirus Biopharmaceuticals and Anavex Life Sciences Corp.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Epirus Biopharmaceuticals -2,025.65% -208.66% -97.67%
Anavex Life Sciences Corp. N/A -95.68% -84.88%

Insider & Institutional Ownership

24.4% of Anavex Life Sciences Corp. shares are owned by institutional investors. 11.6% of Anavex Life Sciences Corp. shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Epirus Biopharmaceuticals has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500. Comparatively, Anavex Life Sciences Corp. has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.

Summary

Anavex Life Sciences Corp. beats Epirus Biopharmaceuticals on 8 of the 9 factors compared between the two stocks.

Epirus Biopharmaceuticals Company Profile

EPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company’s products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.

Anavex Life Sciences Corp. Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

Receive News & Ratings for Epirus Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epirus Biopharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.